Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,861Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M237EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book5.210-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %0.2PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M41,850,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with XBI

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

XBI is held by these investors:

XBI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.48627.95view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94307.38view
DINWOODIE, TYLER WAYNE PAULSenior Officer 2017-01-16Buy4,000$0.1740494.12view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.364974.26view
Bebek, IvanDirector 2017-01-16Buy8,990$3.381941.72view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.4116731.71view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91147.26view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.271000.64view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.3814.29view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1545906.67view

Quarterly/Annual Reports about XBI:

    News about XBI:

    Articles On GuruFocus.com
    Value Investing in BioPharma Nov 18 2015 
    Are Earnings Important? These Days, Revenues Count for More! Mar 17 2014 

    More From Other Websites
    The case for buying the biotech bounce Feb 21 2017
    Biotech ETF Investors are Still on the Sidelines Feb 17 2017
    Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta Feb 17 2017
    Why Gilead's Disastrous Forecast is Good News for Biotech Feb 10 2017
    Leveraged ETFs: How Are They Built and What's Hot Now? Feb 09 2017
    Oppenheimer: Currency FX on Rx Feb 08 2017
    5 reasons to bank on biotech stocks now Feb 05 2017
    The Week Ahead: Trump's 1st Quarter - Pain Or Gain? Feb 03 2017
    Trader's Daily Notebook: Post-Election Rally in Small-Caps Isn't Over Yet Feb 01 2017
    Making pharma great again? Jan 31 2017
    Stock Market Roundup Jan. 31: Nasdaq Rebounds Amid Trump Biotech Meeting Jan 31 2017
    Wall Street Ends January on Weak Note as Washington Division Deepens Jan 31 2017
    Volatile biotech trade illustrates Trump’s ability to shift sentiment on a dime Jan 31 2017
    Biotech Stocks Gain on Latest Trump Drug Price Statements Jan 31 2017
    President Trump Doubles Down On Healthcare Criticism, Says Drug Prices Are 'Astronomical' Jan 31 2017
    Trump, at Biopharma Meeting, Pledges to 'Streamline' FDA, Cut Regulations but Wants Lower Prices Jan 31 2017
    What Lies Ahead for Biotech ETFs in Trump Era? Jan 27 2017
    Biotech ETFs: Is It Time To Buy? Jan 26 2017
    4 Top Biotech Mutual Funds for 2017 Jan 18 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)